Application of combined marker and kit thereof in screening of gastric cancer high-risk population or detection of early gastric adenocarcinoma

Combined markers MUC5AC, MUC6, TFF2, GKN2, PDE4D and CAMK1D were screened through single-cell transcriptome sequencing technology, which is used to screen people with high risk of gastric cancer and early stage gastric adenocarcinoma, solving the problem of insufficient gastric cancer screening in the prior art and improving the The accuracy of diagnosis and the possibility of early detection.

CN119020494APending Publication Date: 2024-11-26SHANDONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411235086.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art is difficult to effectively screen people at high risk of gastric cancer and early gastric adenocarcinoma, especially in areas with low gastroscopy technology, which has led to the fact that most gastric cancer patients are found in the middle and late stages, with a low 5-year survival rate.

Method used

Using single-cell transcriptome sequencing technology, the relative expression levels of combined markers MUC5AC, MUC6, TFF2, GKN2, PDE4D and CAMK1D were screened for detection of high risk of gastric cancer. Kits for population and early stage gastric adenocarcinoma.

Benefits of technology

By detecting the expression levels of these markers, it can effectively distinguish between normal gastric mucosa and early precancerous lesions, improving the screening of high-risk gastric cancer populations and the detection accuracy of early gastric adenocarcinoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020494A_ABST
    Figure CN119020494A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, and provides application of a combined marker and a kit thereof in screening of gastric cancer high-risk groups or detection of early gastric adenocarcinoma. According to the invention, differentially expressed genes in the process of developing normal gastric mucosa into early gastric cancer are analyzed from a single cell level, and six molecular markers, namely MUC5AC, MUC6, TFF2, GKN2, PDE4D and CAMK1D, which are closely related to malignant transformation of gastric mucosa are screened out. Expression of the six molecular markers is verified in a clinical specimen, normal gastric mucosa and precancerous lesions of early gastric cancer can be well distinguished, and screening of high-risk groups of gastric cancer and detection of early gastric adenocarcinoma are facilitated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and particularly relates to an application of a combined marker and a kit thereof in the screening of a high-risk population for gastric cancer or the detection of early gastric adenocarcinoma. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Gastric cancer is one of the common malignant tumors that seriously affects human life and health. It ranks among the top five causes of tumor incidence and cancer-related deaths in the world. At present, due to the low universal coverage rate of gastroscopy technology in some areas, early screening of gastric cancer is insufficient. Once discovered, most gastric cancer patients are often in the middle and late stages, with a low 5-year survival rate. Gastric adenocarcinoma is the most common subtype of gastric cancer in some areas. It has a distinctive progressive evolution process, from normal gastric mucosa, through chronic superficial gastritis, atrophic gastritis with intestinal metaplasia, atypical hyperplasia (precancerous lesions), and finally develops into early gastric cancer. Gastric adenocarcinoma is a complex disease with high heterogeneity. The heterogeneity between and within tumors poses great challenges to the diagnosis, treatment, and prognosis of gastric adenocarcinoma. Summary of the invention

[0004] In order to solve the above problems, the present invention provides a combination of markers and a kit for use in screening high-risk populations for gastric cancer or detecting early gastric adenocarcinoma. The present invention aims to use single-cell transcriptome sequencing technology to establish a single-cell evolution change model of the malignant transformation of mouse gastric mucosa, explore key molecular markers in the malignant transformation of gastric mucosa, and be beneficial to the screening of high-risk populations for gastric cancer and the detection of early gastric adenocarcinoma.

[0005] In order to achieve the above object, the present invention adopts the following technical solution:

[0006] The first aspect of the present invention provides the use of a reagent for detecting the expression level of a combination marker in the preparation of a composition for screening a high-risk population for gastric cancer or detecting early gastric adenocarcinoma, wherein the combination marker is a combination of the relative expression levels of MUC5AC, MUC6, TFF2, GKN2, PDE4D and CAMK1D.

[0007] In some embodiments, when the gastric mucosa undergoes malignant transformation, the expression of MUC5AC, MUC6, TFF2 and GKN2 is significantly reduced.

[0008] In some embodiments, when malignant transformation of gastric mucosa occurs, the expression of PDE4D and CAMK1D increases significantly.

[0009] In some embodiments, the high-risk population for gastric cancer is a population with malignant transformation of gastric mucosa.

[0010] In some embodiments, the high-risk population for gastric cancer is a high-risk population for gastric adenocarcinoma.

[0011] The second aspect of the present invention provides a kit for screening a high-risk population for gastric cancer or detecting early gastric adenocarcinoma, comprising a reagent for detecting the expression level of a combination marker; the combination marker is a combination of the relative expression levels of MUC5AC, MUC6, TFF2, GKN2, PDE4D and CAMK1D.

[0012] In some embodiments, the high-risk population for gastric cancer is a population with malignant transformation of gastric mucosa.

[0013] In some embodiments, the high-risk population for gastric cancer is a high-risk population for gastric adenocarcinoma.

[0014] In some embodiments, the expression level of a combination of markers in gastric mucosal epithelial cells is detected.

[0015] In some embodiments, if the expression of MUC5AC, MUC6, TFF2 and GKN2 is significantly reduced, and the expression of PDE4D and CAMK1D is significantly increased, it is determined that the gastric mucosa has undergone malignant transformation and the patient belongs to a high-risk group for gastric cancer or an early gastric adenocarcinoma patient.

[0016] Beneficial Effects of the Invention

[0017] The present invention provides a combination of molecular markers and its application in preparing a kit for screening high-risk populations for malignant transformation of gastric mucosa. By analyzing the differentially expressed genes in the process of normal gastric mucosa developing into early gastric cancer at the single cell level, six molecular markers closely related to malignant transformation of gastric mucosa, namely MUC5AC, MUC6, TFF2, GKN2, PDE4D and CAMK1D, were screened out. The expression of the above six molecular markers was verified in clinical specimens, which can well distinguish normal gastric mucosa from early gastric cancer precancerous lesions, which is beneficial to the screening of high-risk populations for gastric cancer and the detection of early gastric adenocarcinoma. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] The accompanying drawings constituting a part of the present invention are used to provide a further understanding of the present invention, and the exemplary embodiments of the present invention and their description are used to explain the present invention and do not constitute improper limitations on the present invention.

[0019] Figure 1 This is the modeling process of the mouse malignant transformation model and the pathological changes of the mouse gastric mucosa.

[0020] Figure 2To use single-cell transcriptome sequencing technology to analyze the changes in different epithelial cell subpopulations during the malignant transformation of gastric mucosa.

[0021] Figure 3 To obtain a set of key molecular markers by analyzing the changes in expression profiles of gastric foveolar cells, mucus neck cells and chief cells in normal gastric mucosal epithelium and malignant transformed epithelium.

[0022] Figure 4 The expression levels of this panel of molecular markers were validated for clinical specimens.

[0023] Figure 5 ROC curve of molecular markers. DETAILED DESCRIPTION

[0024] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0025] The present invention will be further described in detail below in conjunction with specific embodiments. It should be noted that the specific embodiments are intended to explain the present invention rather than to limit it.

[0026] Example 1

[0027] The present invention successfully induced a mouse gastric mucosal malignant transformation model by combining nitrite feeding with chronic restraint stress stimulation.

[0028] The present invention uses C57BL / 6J male mice, feeds them with N-methyl-N-nitrosourea and performs chronic restraint stress stimulation to construct a mouse gastric mucosal malignant transformation model. Pathological diagnosis confirms that the gastric mucosa of the experimental group mice is in a state of atypical hyperplasia at the end of modeling, which is a precancerous lesion state of early gastric cancer ( Figure 1 ).

[0029] Example 2

[0030] The present invention uses single-cell RNA sequencing to identify cell subpopulations in the process of malignant transformation of gastric mucosa

[0031] The present invention uses single-cell RNA sequencing technology to sequence 22,195 single cells from the gastric mucosa of modeling group mice and control group mice, and identifies 6 major cell subpopulations, including epithelial cells, fibroblasts, endocrine cells, immune cells, smooth muscle cells and endothelial cells. 16,442 epithelial cells were re-clustered and divided into 7 epithelial cell subpopulations, including gastric pit cells, parietal cells, spasmolytic polypeptide-expressing metaplastic cells (SPEM), chief cells, proliferative cells, mucus neck cells and stem cells. Among them, SPEM cells have been reported by predecessors to be the source cells of gastric adenocarcinoma. The present invention detects that during the malignant transformation of the gastric mucosa, all cell subtypes may undergo changes in abundance and phenotype. Among them, SPEM cells are enriched in the gastric mucosa of modeling group mice, while chief cells and proliferative cells are significantly reduced in the gastric mucosa of modeling group mice ( Figure 2 ).

[0032] Example 3

[0033] Current research suggests that the malignant transformation of the gastric mucosa begins from the fundic glands and gradually develops to the gastric pits. Therefore, the present invention conducts an in-depth analysis of mucus neck cells, chief cells, and gastric pit cells. The gastric pit cells were re-clustered into 4 major cell subgroups, and the gastric pit cells of normal mice were mainly concentrated in 3 subgroups; the mucus neck cells were re-clustered into 3 major cell subgroups, and the mucus neck cells of normal mice were mainly concentrated in 2 subgroups; the chief cells were re-clustered into 4 major cell subgroups, and the chief cells of normal mice were mainly concentrated in 2 subgroups. By analyzing the changes in the gene expression profiles of normal gastric mucosal epithelial cells and malignantly transformed epithelial cells, the present invention obtained a group of key molecular markers, MUC5AC, MUC6, TFF2, GKN2, PDE4D, and CAMK1D ( Figure 3 ).

[0034] Clinical tissue specimens were collected from Shandong Provincial Maternal and Child Health Hospital. From normal gastric mucosa to intestinal metaplasia, low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia, and early gastric cancer, six specimens were collected in each stage, and two pathology experts made pathological diagnosis for each specimen. The accuracy of this molecular marker combination was further verified by staining clinical specimens of normal gastric mucosa and gastric mucosa at different stages of lesion progression. Among them, the expression of four molecules, MUC5AC, MUC6, TFF2 and GKN2, was significantly reduced when malignant transformation occurred, while the expression of PDE4D and CAMK1D was significantly increased ( Figure 4 ).

[0035] In order to obtain the specificity and sensitivity of these six key molecular markers in identifying malignant transformation of gastric mucosa, the immunohistochemistry of normal gastric mucosa and intestinal metaplasia was quantitatively scored. Five fields of view were randomly intercepted from each slice. The immunohistochemistry results were relatively quantified using ImageJ software, and the staining components (diaminobenzidine and hematoxylin) were separated by color deconvolution, and the average optical density (AOD) value of the positive staining area was calculated. 8 software performed receiver operating characteristic (ROC) curve analysis on the specificity and sensitivity of these six key molecular markers, showing that MUC5AC (area under the curve AUC = 0.8475, 95% confidence interval 0.7183-0.9767, P = 0.0002), MUC6 (area under the curve AUC = 0.8950, 95% confidence interval 0.7829-1.000, P < 0.0001), TFF2 (area under the curve AUC = 0.8000, 95% confidence interval 0.6610-0.9390, P = 0.0012), GKN2 (area under the curve AUC = 0.9425, 95% confidence interval 0.8757-1.0000, P < 0.0001), PDE4D (area under the curve AUC = 0.8400, 95% confidence interval 0.6978-0.9822, P = 0.0002) and CAMK1D (area under the curve AUC = 0.9625, 95% confidence interval 0.9071-1.0000, P < 0.0001), all of which have a good ability to distinguish normal gastric mucosa from intestinal metaplasia ( Figure 5 ).

[0036] The present invention provides a combination of molecular markers and its application in preparing a kit for screening high-risk populations for malignant transformation of gastric mucosa. By analyzing the differentially expressed genes in the process of normal gastric mucosa developing into early gastric cancer at the single cell level, six molecular markers closely related to malignant transformation of gastric mucosa, namely MUC5AC, MUC6, TFF2, GKN2, PDE4D and CAMK1D, were screened out. The expression of the above six molecular markers was verified in clinical specimens, which can well distinguish normal gastric mucosa from early gastric cancer precancerous lesions, which is beneficial to the screening of high-risk populations for gastric cancer and the detection of early gastric adenocarcinoma.

[0037] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of a reagent for detecting the expression level of a combination marker in the preparation of a composition for screening a high-risk population for gastric cancer or detecting early gastric adenocarcinoma, It is characterized in that The combined marker is a combination of relative expression levels of MUC5AC, MUC6, TFF2, GKN2, PDE4D and CAMK1D.

2. The use according to claim 1, It is characterized in that When the gastric mucosa undergoes malignant transformation, the expressions of MUC5AC, MUC6, TFF2 and GKN2 are significantly reduced.

3. The use according to claim 1, It is characterized in that When the gastric mucosa undergoes malignant transformation, the expression of PDE4D and CAMK1D increases significantly.

4. The use according to claim 1, It is characterized in that The high-risk population for gastric cancer is a population with malignant transformation of gastric mucosa.

5. The use according to claim 1, It is characterized in that The high-risk population for gastric cancer is a high-risk population for gastric adenocarcinoma.

6. A kit for screening high-risk populations for gastric cancer or detecting early gastric adenocarcinoma, It is characterized in that The invention comprises reagents for detecting the expression level of a combination marker; the combination marker is a combination of the relative expression levels of MUC5AC, MUC6, TFF2, GKN2, PDE4D and CAMK1D.

7. The kit for screening a high-risk population for gastric cancer or detecting early gastric adenocarcinoma according to claim 6, It is characterized in that The high-risk population for gastric cancer is a population with malignant transformation of gastric mucosa.

8. The kit for screening a high-risk population for gastric cancer or detecting early gastric adenocarcinoma according to claim 6, It is characterized in that The high-risk population for gastric cancer is a high-risk population for gastric adenocarcinoma.

9. The kit for screening a high-risk population for gastric cancer or detecting early gastric adenocarcinoma according to claim 6, It is characterized in that The expression levels of combined markers in gastric mucosal epithelial cells were detected.

10. The kit for screening a high-risk population for gastric cancer or detecting early gastric adenocarcinoma according to claim 6, It is characterized in that If the expression of MUC5AC, MUC6, TFF2 and GKN2 is significantly decreased, and the expression of PDE4D and CAMK1D is significantly increased, it is judged that the gastric mucosa has undergone malignant transformation, and the patient belongs to the high-risk group for gastric cancer or the early gastric adenocarcinoma patient.